Reference: Sinning et al. AHJ Am Heart J 2012;164:102-110
Percutaneous aortic valve replacement (TAVI) is a novel technique for the treatment of severe aortic stenosis (SAS) that has been built with great enthusiasm in clinical practice, particularly in patients with excessive surgical risk. In these patients, a high obstructive peripheral vascular disease stands, a fact playing an important role in determining the best vascular access during the procedure.
A recent study evaluated the presence of peripheral vascular disease impact over clinical course of patients undergoing TAVI yielding the following results:
